Release Date: March 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: How do you think the FDA's compassionate use withdrawal will impact the competitive landscape for gastroparesis treatments? A: Matthew D'Onofrio, CEO, stated that it's uncertain when the Dam Paradigm component will run out, but it's likely that patients will need alternatives like Jamodi. Chris Quesenberry, Chief Commercial Officer, added that the withdrawal cements Evoke as a leader in the market, providing an option for patients and providers.
Q: Can you provide an update on the strategy to increase Medicaid and Medicare pharmacy presence? A: Chris Quesenberry explained that the strategy has been successful, with Medicaid prescriptions growing from 2% to between 5% and 7% of their business. The addition of seven dispensing pharmacies has improved conversion rates, and they expect continued growth as they demonstrate their ability to fill prescriptions.
Q: What are the financial highlights for the fourth quarter and full year of 2024? A: Mark Kowieski, CFO, reported net product sales of $3.3 million for Q4 2024, up from $1.7 million in Q4 2023. The net loss was $1.2 million, an improvement from $2 million in the previous year. For the full year, net product sales were $10.2 million, with a net loss of $5.4 million, showing significant revenue growth and reduced losses.
Q: What are Evoke Pharma's strategic priorities for 2025? A: Matthew D'Onofrio outlined plans to expand pharmacy partnerships, increase provider awareness, leverage real-world data, and improve prescription fulfillment rates. The company aims to make Jamodi the standard of care for gastroparesis treatment while maintaining disciplined capital allocation.
Q: How has the transition to Aspen pharmacies impacted Evoke Pharma's operations? A: The transition has significantly accelerated delivery times for Jamodi and improved insurance authorization processes. This has led to a 46% increase in prescribers and a 72% increase in fill rates year over year, enhancing overall patient experience and adherence.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.